ArticleQuantitative imaging in medicine and surgery2025
First-phase ejection fraction as a potential early indicator for left ventricular function in cardiac amyloidosis.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiac amyloidosis (CA) is crucial for prognosis in patients with light-chain amyloidosis, with left ventricular first-phase ejection fraction (LVEF1) being a more sensitive indicator for this condition than ejection fraction. This study aimed to assess LVEF1's value in informing the treatment and prognosis of patients with light-chain CA. Methods: A total of 119 patients with light-chain amyloidosis and LVEF ≥50% and suspected CA according to echocardiography were enrolled. After validation via cardiac magnetic resonance (CMR) or abdominal fat biopsy, these patients were split into a CA group (n=72) and non-CA group (n=47). Based on first hospitalization, echocardiography and blood biochemical data were obtained. After 1 year of chemotherapy, echocardiography and biochemical data were obtained again, and patients were divided into hematologic complete response (hemCR; n=26) and non-hemCR (n=38) groups. Analyses of subgroups comparing pre- and posttreatment were conducted, followed by survival analysis in all patients with CA (followed up until September 30, 2024). Results: Compared to the non-CA group, the CA group had a lower LVEF1 (31.35%±7.78% Conclusions: LVEF1 has the potential to be an early indicator of left ventricular function in patients with CA and preserved ejection fraction. It can both reflect subtle left ventricular function changes and aid in predicting prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.